Form 4: Neogenomics Director Stephen M. Kanovsky Acquires 4,000 Shares of Common Stock
SEC Form 4
Director Stephen M. Kanovsky purchased 4,000 shares of Neogenomics Inc. common stock at $7.7811 per share on May 7, 2025, increasing his total holdings to 40,090 shares.
Summary
- On May 7, 2025, Stephen M. Kanovsky, a director of Neogenomics Inc., acquired 4,000 shares of common stock at a price of $7.7811 per share.
- This transaction increased Kanovsky's direct ownership to 40,090 shares of Neogenomics common stock.
- Kanovsky also holds multiple stock options with varying exercise prices and expiration dates, as well as restricted stock units.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the director's purchase of shares, indicating confidence in the company. However, it's a single transaction and needs to be considered in the context of overall market conditions and company performance.
Positives
- A director's purchase of company stock can be seen as a positive signal, indicating confidence in the company's future prospects.
Industry Context
Insider buying is often monitored by investors as an indicator of management's and directors' confidence in the company's prospects. It can be a positive signal, especially when compared to insider selling.
Comparison to Industry Standards
- Comparing insider transactions at Neogenomics to those of its competitors in the diagnostics and cancer testing industry, such as Exact Sciences or Guardant Health, can provide a broader context.
- For example, if other directors or executives at Neogenomics have also been purchasing shares, or if the volume of insider buying is higher than the industry average, it could be a stronger signal of positive sentiment.
Stakeholder Impact
- The director's stock purchase could positively influence shareholder sentiment.
- It may also boost employee morale by signaling confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 06/06/2020 | Date exercisable for stock options to buy 4,269 shares at $22.52, expiring 06/06/2026 |
| 05/28/2021 | Date exercisable for stock options to buy 3,448 shares at $28.54, expiring 05/28/2027 |
| 06/02/2022 | Date exercisable for stock options to buy 3,714 shares at $40.9, expiring 06/02/2028 |
| 06/10/2023 | Date exercisable for stock options to buy 13,882 shares at $8.1, expiring 06/10/2029 |
| 08/10/2024 | Date exercisable for stock options to buy 8,353 shares at $14.82, expiring 08/10/2033 |
| 05/07/2025 | Date of director's stock purchase of 4,000 shares at $7.7811 per share |
| 06/01/2025 | Date exercisable for stock options to buy 8,672 shares at $13.71, expiring 06/01/2034 and vesting date for 12,254 restricted stock units |
| 06/06/2026 | Expiration date for stock options to buy 4,269 shares at $22.52 |
| 05/28/2027 | Expiration date for stock options to buy 3,448 shares at $28.54 |
| 06/02/2028 | Expiration date for stock options to buy 3,714 shares at $40.9 |
| 06/10/2029 | Expiration date for stock options to buy 13,882 shares at $8.1 |
| 08/10/2033 | Expiration date for stock options to buy 8,353 shares at $14.82 |
| 06/01/2034 | Expiration date for stock options to buy 8,672 shares at $13.71 |
Keywords
Neogenomics, Director, Stock Purchase, Common Stock, Beneficial Ownership, Options, Restricted Stock Units, Insider Trading
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.